Меню
Идёт набор NCT07595094

Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases

— Наблюдательное Phenotypic Age Acceleration Biological Aging Marker Mortality Risk Prediction Disease Risk Prediction

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: No Intervention (Observational Study).
Кому может быть актуально
Состояния в реестре: Phenotypic Age Acceleration, Biological Aging Marker, Mortality Risk Prediction, Disease Risk Prediction. Базовые параметры: от 35 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

The goal of this observational study is to learn about the ability of Phenotypic Age Acceleration (PhenoAgeAccel) to predict four key health outcomes in Chinese people with or at risk of major chronic diseases: the risk of developing new chronic diseases, the risk of dying, life expectancy, and disease-free healthspan. The main questions this study aims to answer are: * Does higher PhenoAgeAccel increase the risk of developing major chronic diseases (including diabetes, dementia, cancer, and chronic respiratory diseases) in Chinese adults? * Does higher PhenoAgeAccel increase the risk of death from all causes in Chinese adults? * How do life expectancy and disease-free healthspan differ between people with high versus low PhenoAgeAccel? Who can take part in this study? Adults aged 35 or above years old who receive routine care at participating hospitals in China, have complete routine blood test data available, and have provided consent to use their health information for research purposes. What will participants go through? Participants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. We will collect data from their medical records, including blood test results used to calculate PhenoAgeAccel, diagnoses of new diseases, and dates of death. What are the potential benefits? Participants will not receive direct personal benefits from taking part in this study. However, the information learned may help us better understand biological aging and improve future risk assessment and health management for people with chronic diseases. Is this study safe? Yes. This is an observational study that does not involve any new drugs, devices, or invasive procedures. All data used in the study will be de-identified and kept strictly confidential to protect participants' privacy.

Вмешательства

  • Другое No Intervention (Observational Study)
    This is an observational study with no study-specific intervention. All participants receive their routine standard medical care as usual. No new drugs, devices, procedures, or behavioral modifications are assigned as part of this research.

Первичные конечные точки

  • Incidence of Major Chronic Diseases [Срок оценки: Baseline through study completion, average 10 years]
  • All-Cause Mortality [Срок оценки: Baseline through study completion, average 10 years]
Вторичные конечные точки (2)
  • Life Expectancy [Срок оценки: Baseline through study completion, average 10 years]
  • Disease-Free Healthspan [Срок оценки: Baseline through study completion, average 10 years]

Критерии участия

Критерии включения

  • Adults aged 35-73 years old. Complete routine blood test data available at baseline to calculate Phenotypic -Age (including albumin, alkaline phosphatase, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red cell distribution width, and white blood cell count).

Complete demographic and clinical data (e.g., sex, BMI, comorbidities) available at baseline.

  • Consent to use routine medical data for research follow-up analysis.

Критерии исключения

  • Presence of end-stage diseases (e.g., end-stage liver/renal failure) other than the major chronic diseases of interest at baseline.
  • Key baseline data missing, making Phenotypic Age calculation impossible. Incomplete follow-up information or inability to confirm outcomes (e.g., death, disease onset) via database linkage.
  • Refusal to participate in the study or withdrawal of informed consent.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Китай · 1 центр
  • Second Affiliated Hospital of Nanchang University — Nanchang

Идентификаторы

NCT: NCT07595094 · IIT-O-2024-136

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗